Compounds > binifibrate
Page last updated: 2024-12-06

binifibrate

Description

Binifibrate is a fibrate drug used to lower cholesterol levels. It is a synthetic compound that acts as an agonist of peroxisome proliferator-activated receptor alpha (PPARα). PPARα is a nuclear receptor that plays a role in lipid metabolism and the regulation of cholesterol levels. Binifibrate is studied for its potential benefits in treating hyperlipidemia, a condition characterized by high levels of cholesterol in the blood. It is also being investigated for its potential role in preventing cardiovascular disease. Binifibrate is synthesized through a multi-step process involving various chemical reactions. The specific synthesis route is complex and involves several intermediates. It is important to note that the information provided here is for general knowledge purposes only and should not be construed as medical advice.'

binifibrate: two nicotinic & one clofibiric radical esterified by glycerol moiety [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID68884
CHEMBL ID2106582
CHEBI ID135800
SCHEMBL ID49116
MeSH IDM0116778

Synonyms (33)

Synonym
wac-104
binifibrate
biniwas
binifibrato
antopal retard
wac 104
2-(p-chlorophenoxy)-2-methylpropionic acid ester with 1,3-dinicotininoyloxy-2-propanol
binifibrato [inn-spanish]
glyceryl 2-p-chlorophenoxyisobutyrate-1,3-dinicotinate
binifibratum [inn-latin]
3-pyridinecarboxylic acid, 2-(2-(4-chlorophenoxy)-2-methyl-1-oxopropoxy)-1,3-propanediyl ester
trihydroxypropane 2-p-chlorophenoxyisobutyrate-1,3-dinicotinate
binifibrate [inn]
69047-39-8
biniwas (tn)
D07529
binifibrate (inn)
CHEBI:135800
[2-[2-(4-chlorophenoxy)-2-methylpropanoyl]oxy-3-(pyridine-3-carbonyloxy)propyl] pyridine-3-carboxylate
binifibratum
9ngz4gpe20 ,
unii-9ngz4gpe20
CHEMBL2106582
binifibrate [mart.]
binifibrate [mi]
binifibrate [who-dd]
3-pyridinecarboxylicacid, 3,3'-[2-[2-(4-chlorophenoxy)-2-methyl-1-oxopropoxy]-1,3-propanediyl]ester
SCHEMBL49116
DTXSID80219113
Q12200764
CS-0066932
HY-116977
AKOS040747983

Research Excerpts

Treatment

ExcerptReferenceRelevance
"The treatment with binifibrate was applied at a dosage of 3 X 600 mg/day during one month."( Microhaemorheological properties of binifibrate. Part II: Preliminary open studies in patients with peripheral arteriopathies.
Andreoli, R; Bruseghini, L; Dalmau, M; Diez, S; Freixes, J; Monasterio, J; Nogués, R; Picó, M, 1983)		0.86

Dosage Studied

ExcerptRelevanceReference
" The treatment with binifibrate was applied at a dosage of 3 X 600 mg/day during one month."( Microhaemorheological properties of binifibrate. Part II: Preliminary open studies in patients with peripheral arteriopathies.
Andreoli, R; Bruseghini, L; Dalmau, M; Diez, S; Freixes, J; Monasterio, J; Nogués, R; Picó, M, 1983)		0.86
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
monocarboxylic acidAn oxoacid containing a single carboxy group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (25.00)18.7374
1990's5 (62.50)18.2507
2000's0 (0.00)29.6817
2010's1 (12.50)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (25.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (75.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
niacin
Niacin: A water-soluble vitamin of the B complex occurring in various animal and plant tissues. It is required by the body for the formation of coenzymes NAD and NADP. It has PELLAGRA-curative, vasodilating, and antilipemic properties.. vitamin B3 : Any member of a group of vitamers that belong to the chemical structural class called pyridines that exhibit biological activity against vitamin B3 deficiency. Vitamin B3 deficiency causes a condition known as pellagra whose symptoms include depression, dermatitis and diarrhea. The vitamers include nicotinic acid and nicotinamide (and their ionized and salt forms).. nicotinic acid : A pyridinemonocarboxylic acid that is pyridine in which the hydrogen at position 3 is replaced by a carboxy group.		1.9710pyridine alkaloid;
pyridinemonocarboxylic acid;
vitamin B3		antidote;
antilipemic drug;
EC 3.5.1.19 (nicotinamidase) inhibitor;
Escherichia coli metabolite;
human urinary metabolite;
metabolite;
mouse metabolite;
plant metabolite;
vasodilator agent
clofibric acid
Clofibric Acid: An antilipemic agent that is the biologically active metabolite of CLOFIBRATE.. clofibric acid : A monocarboxylic acid that is isobutyric acid substituted at position 2 by a p-chlorophenoxy group. It is a metabolite of the drug clofibrate.		1.9710aromatic ether;
monocarboxylic acid;
monochlorobenzenes		anticholesteremic drug;
antilipemic drug;
antineoplastic agent;
herbicide;
marine xenobiotic metabolite;
PPARalpha agonist
gemfibrozil
[no description available]		8.3711aromatic etherantilipemic drug
streptomycin
[no description available]		2.1110antibiotic antifungal drug;
antibiotic fungicide;
streptomycins		antibacterial drug;
antifungal agrochemical;
antimicrobial agent;
antimicrobial drug;
bacterial metabolite;
protein synthesis inhibitor
fibrinogen
Fibrinogen: Plasma glycoprotein clotted by thrombin, composed of a dimer of three non-identical pairs of polypeptide chains (alpha, beta, gamma) held together by disulfide bonds. Fibrinogen clotting is a sol-gel change involving complex molecular arrangements: whereas fibrinogen is cleaved by thrombin to form polypeptides A and B, the proteolytic action of other enzymes yields different fibrinogen degradation products.. D-iditol : The D-enantiomer of iditol.		3.3811iditolfungal metabolite
ConditionIndicatedRelationship StrengthStudiesTrials
Vascular Diseases
Pathological processes involving any of the BLOOD VESSELS in the cardiac or peripheral circulation. They include diseases of ARTERIES; VEINS; and rest of the vasculature system in the body.		01.9610
Hyperlipemia
[description not available]		04.8442
Hyperlipidemias
Conditions with excess LIPIDS in the blood.		04.8442
Elevated Cholesterol
[description not available]		03.3811
Hypercholesterolemia
A condition with abnormally high levels of CHOLESTEROL in the blood. It is defined as a cholesterol value exceeding the 95th percentile for the population.		03.3811
Hypertriglyceridemia
A condition of elevated levels of TRIGLYCERIDES in the blood.		03.3811
chemdatabank.com